Strides Pharma Science Limited

Total Valuation

Strides Pharma Science Limited carries a market capitalization of 103.36B, placing it among publicly traded companies globally. Its enterprise value stands at 82.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Valuation Ratios

Strides Pharma Science Limited trades at a trailing price-to-earnings ratio of 24.23.

Enterprise Valuation

On an enterprise value basis, Strides Pharma Science Limited trades at an EV/EBITDA multiple of 13.01 and an EV/FCF ratio of 44.83. The EV/Sales ratio of 1.79 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 13.01 provides insight into valuation relative to core operating earnings.

Financial Position

Strides Pharma Science Limited maintains a current ratio of 2.24, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 176.89, indicating elevated leverage, while an interest coverage ratio of 2.84 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Strides Pharma Science Limited has paid 749.51M in income taxes, reflecting an effective tax rate of 17.49.

Stock Price Statistics

Strides Pharma Science Limited's stock has gained approximately 28.74526% over the past 52 weeks. The 50-day moving average sits at 1,100.22, while the 200-day moving average is 944.62.

Income Statement

Over the trailing twelve months, Strides Pharma Science Limited generated 46.31B in revenue and converted that into 3.42B in net income, yielding earnings per share of 38.38. EBITDA reached 6.36B, while operating income came in at 6.36B.

Margins

Strides Pharma Science Limited operates with a gross margin of 57.36, reflecting its pricing power and cost economics. The operating margin of 13.74 and net profit margin of 7.38 provide insight into operational efficiency.

Stock Splits

Strides Pharma Science Limited's most recent stock split took place on December 6, 2024 with a 3329:8000 split ratio.

Scores

Strides Pharma Science Limited posts an Altman Z-Score of 4.87, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.